The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases

被引：0
|
作者：
Maio, Michele
Testori, Alessandro
Ascierto, Paolo Antonio
Ridolfi, Ruggero
Santinami, Mario
Pilla, Lorenzo
Queirolo, Paola
Grosso, Marco
Simeone, Ester
Vittoria, Stefania
Nicoletti, Luisa
Rivoltini, Licia
Ferrucci, Pier Francesco
Parmiani, Giorgio
Di Giacomo, Anna Maria
机构：
[1] Univ Hosp Siena, Siena, Italy
[2] European Inst Oncol, Milan, Italy
[3] Ist Nazl Tumori Fdn Pascale, Unit Med Oncol & Innovat Therapy, Naples, Italy
[4] IRST, Immuntherapy Unit, Meldola, Italy
[5] Fdn Ist Nazl Tumori, Milan, Italy
[6] San Raffaele Sci, Mol Oncol, Milan, Italy
[7] Univ Inst, Milan, Italy
[8] Natl Inst Canc Res, Genoa, Italy
[9] Ist Nazl Tumori Pascale, Naple, Italy
[10] IRST, Meldola, Italy
[11] Natl Canc Inst, I-20133 Milan, Italy
[12] Ist Sci San Raffaele, I-20132 Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8529
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial
    Di Giacomo, A. M.
    Ascierto, P. A.
    Pittiglio, E.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Parmiani, G.
    Maio, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S653 - S654
  • [2] A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial.
    Di Giacomo, A. M.
    Ascierto, P. A.
    Fonsatti, E.
    Pittiglio, E.
    Queirolo, P.
    Pilla, L.
    Ridolfi, R.
    Santinami, M.
    Testori, A.
    Parmiani, G.
    Maio, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study
    Maccalli, Cristina
    Giannarelli, Diana
    Capocefalo, Filippo
    Pilla, Lorenzo
    Fonsatti, Ester
    Di Giacomo, Anna Maria
    Parmiani, Giorgio
    Maio, Michele
    [J]. ONCOIMMUNOLOGY, 2016, 5 (02):
  • [4] Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
    Di Giacomo, A. M.
    Sileni, V. Chiarion
    Del Vecchio, M.
    Ferrucci, P. F.
    Guida, M.
    Quaglino, P.
    Guidoboni, M.
    Marchetti, P.
    Cutaia, O.
    Amato, G.
    Gambale, E.
    Calabro, L.
    Valente, M.
    Danielli, R.
    Giannarelli, D.
    Mandala, M.
    Maio, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S734 - S734
  • [5] Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
    Di Giacomo, Anna Maria
    Ascierto, Paolo A.
    Pilla, Lorenzo
    Santinami, Mario
    Ferrucci, Pier Francesco
    Giannarelli, Diana
    Marasco, Antonella
    Rivoltini, Licia
    Simeone, Ester
    Nicoletti, Stefania V. L.
    Fonsatti, Ester
    Annesi, Diego
    Queirolo, Paola
    Testori, Alessandro
    Ridolfi, Ruggero
    Parmiani, Giorgio
    Maio, Michele
    [J]. LANCET ONCOLOGY, 2012, 13 (09): : 879 - 886
  • [6] A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.
    Di Giacomo, Anna Maria
    Annesi, Diego
    Ascierto, Paolo Antonio
    Calabro, Luana
    Chiarion-Sileni, Vanna
    Danielli, Riccardo
    Del Vecchio, Michele
    Ferraresi, Virginia
    Ferrucci, Pier Francesco
    Fonsatti, Ester
    Guida, Michele
    Giannarelli, Diana
    Guidoboni, Massimo
    Mandala, Mario
    Quaglino, Pietro
    Queirolo, Paola
    Maccalli, Cristina
    Parmiani, Giorgio
    Maio, Michele
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with melanoma with brain metastasis: The NIBIT-M2 study
    Di Giacomo, A. M.
    Maio, M.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 5 - 5
  • [8] Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
    Di Giacomo, Anna Maria
    Covre, Alessia
    Finotello, Francesca
    Rieder, Dietmar
    Danielli, Riccardo
    Sigalotti, Luca
    Giannarelli, Diana
    Petitprez, Florent
    Lacroix, Laetitia
    Valente, Monica
    Cutaia, Ornella
    Fazio, Carolina
    Amato, Giovanni
    Lazzeri, Andrea
    Monterisi, Santa
    Miracco, Clelia
    Coral, Sandra
    Anichini, Andrea
    Bock, Christoph
    Nemc, Amelie
    Oganesian, Aram
    Lowder, James
    Azab, Mohammad
    Fridman, Wolf H.
    Sautes-Fridman, Catherine
    Trajanoski, Zlatko
    Maio, Michele
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7351 - 7362
  • [9] Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.
    Di Giacomo, Anna Maria
    Ascierto, Paolo Antonio
    Pilla, Lorenzo
    Ridolfi, Ruggero
    Santinami, Mario
    Testori, Alessandro
    Queirolo, Paola
    Simeone, Ester
    Guidoboni, Massimo
    Del Vecchio, Michele
    Ferrucci, Pier Francesco
    Marasco, Antonella
    Fonsatti, Ester
    Annesi, Diego
    Giannarelli, Diana
    Parmiani, Giorgio
    Maio, Michele
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
    Di Giacomo, A. M.
    Sileni, V. Chiarion
    Del Vecchio, M.
    Ferrucci, P. F.
    Guida, M.
    Quaglino, P.
    Guidoboni, M.
    Marchetti, P.
    Simonetti, E.
    Amato, G.
    Covre, A.
    Camerini, R.
    Calabro, L.
    Valente, M.
    Mandala, M.
    Giannarelli, D.
    Maio, M.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S653 - S654
12345